Alignment Healthcare, Inc. (ALHC) Stock Price & Analysis
Alignment Healthcare, Inc. (ALHC) closed at USD 8.43 on Thursday, October 22, 2026, down 0.12% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 8.44; the Oct 22, 2026 session ranged USD 8.35–8.55 on volume of 3,037,405 shares. Market capitalization is $1.75B, with a 52-week range of USD 6.01–25.12 (NMS). Source: Nexqual, retrieved October 23, 2026 at 10:07 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ALHC.md
Key facts (ALHC)
- Last four reported quarters (through Jun 30, 2026): revenue $4.58B, net income $40.7M (0.9% margin), free cash flow $178M (SEC filings).
- Valuation: P/E 43.0x, EV/EBITDA 15.8x, net cash $378M.
- Earnings quality: non-operating income -$16.2M vs operating income $55.0M over the last four quarters; P/E excluding non-operating income ≈30.7x (estimate: non-operating income taxed at the company's 0% effective rate).
- Insider open-market sales, last ~7 months: 22 Form 4 filings, $50.7M; 4 not under a Rule 10b5-1 plan ($2.3M); 0 by opportunistic insiders, 19 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Insider open-market purchases, last ~7 months: 1 Form 4 filing, $198K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 2.07 on a 1–5 scale) (14 analysts), mean target USD 12.31 (range 9–26).
- Total return with dividends: 1Y -51.2% vs S&P 500 +14.9%; 5Y -57.4% vs S&P 500 +80.3%.
- Next earnings: 2026-10-29, EPS estimate USD 0.04, revenue estimate $1.31B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ALHC)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $1.17B | $1.43B | $1.82B | $2.70B | $3.95B | $4.58B |
| Operating income | -$178M | -$129M | -$128M | -$102M | $14.8M | $55.0M |
| Net income | -$195M | -$150M | -$148M | -$128M | -$724K | $40.7M |
| EPS (diluted) | -$1.14 | -$0.83 | -$0.79 | -$0.67 | $0.00 | — |
| Free cash flow | — | -$69.2M | -$95.2M | -$6.6M | $113M | $178M |
| Operating margin | -15.2% | -9.0% | -7.0% | -3.8% | 0.4% | 1.2% |
| Net margin | -16.7% | -10.4% | -8.1% | -4.7% | 0.0% | 0.9% |
| Revenue growth | +21.7% | +22.8% | +27.2% | +48.3% | +46.1% | — |
| Cash + short-term investments | $467M | $410M | $319M | $471M | $604M | — |
| Total debt | $151M | $161M | $162M | $321M | $323M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (ALHC)
P/E 43.0x · P/E ex non-operating (est.) ≈30.7x · P/S 0.4x · EV/EBITDA 15.8x · EV/Sales 0.3x · P/FCF 9.9x · P/B 6.6x · FCF yield 10.15% · Earnings yield 2.33% · Net cash $378M · EV $1.37B
Insider sales (SEC Form 4, open-market, last ~7 months) (ALHC)
18 of 22 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-06 | Kim Hyong | Chief Medical Officer | 32,479 | $270K | 9.8% | No | Too little history (no open-market trades in 2023) |
| 2026-09-17 | Konowiecki Joseph S | EVP, Corporate Affairs | 23,511 | $202K | 2.1% | No | Routine (sold in Nov each year 2023–2025; this trade is outside those months) |
| 2026-09-14 | Kao John E | Chief Executive Officer | 27,400 | $356K | 1.5% | Yes | Routine (traded in Mar each year 2023–2025; this trade is outside those months) |
| 2026-09-11 | Maroney Dawn Christine | President | 122,707 | $1.6M | 13.4% | No | Routine (sold in Mar each year 2023–2025; this trade is outside those months) |
| 2026-09-10…2026-09-11 | Kao John E | Chief Executive Officer | 557,870 | $7.1M | 23.2% | Yes | Routine (traded in Mar each year 2023–2025; this trade is outside those months) |
| 2026-08-14 | Maroney Dawn Christine | President | 5,000 | $70K | 0.5% | Yes | Routine (sold in Mar each year 2023–2025; this trade is outside those months) |
| 2026-08-10 | Kao John E | Chief Executive Officer | 298,000 | $4.1M | 11% | Yes | Routine (traded in Mar each year 2023–2025; this trade is outside those months) |
| 2026-07-15 | Maroney Dawn Christine | President | 177,068 | $3.7M | 16.1% | Yes | Routine (sold in Mar each year 2023–2025; this trade is outside those months) |
| 2026-07-10 | Kao John E | Chief Executive Officer | 298,000 | $5.9M | 9.9% | Yes | Routine (traded in Mar each year 2023–2025; this trade is outside those months) |
| 2026-07-01 | Konowiecki Joseph S | EVP, Corporate Affairs | 25,000 | $600K | 2.2% | Yes | Routine (sold in Nov each year 2023–2025; this trade is outside those months) |
| 2026-06-26 | Konowiecki Joseph S | EVP, Corporate Affairs | 25,000 | $575K | 2.2% | Yes | Routine (sold in Nov each year 2023–2025; this trade is outside those months) |
| 2026-06-18 | Konowiecki Joseph S | EVP, Corporate Affairs | 25,000 | $550K | 2.1% | Yes | Routine (sold in Nov each year 2023–2025; this trade is outside those months) |
| 2026-06-15 | Maroney Dawn Christine | President | 30,000 | $586K | 3.1% | Yes | Routine (sold in Mar each year 2023–2025; this trade is outside those months) |
| 2026-06-12 | Kim Hyong | Chief Medical Officer | 35,951 | $714K | 9.8% | Yes | Too little history (no open-market trades in 2023) |
| 2026-06-11 | Konowiecki Joseph S | EVP, Corporate Affairs | 25,000 | $525K | 2.1% | Yes | Routine (sold in Nov each year 2023–2025; this trade is outside those months) |
| 2026-06-10 | Kao John E | Chief Executive Officer | 298,000 | $6.1M | 9% | Yes | Routine (traded in Mar each year 2023–2025; this trade is outside those months) |
| 2026-05-15 | Maroney Dawn Christine | President | 30,000 | $483K | 3% | Yes | Routine (sold in Mar each year 2023–2025; this trade is outside those months) |
| 2026-05-11 | Kao John E | Chief Executive Officer | 298,000 | $5.0M | 8.3% | Yes | Routine (traded in Mar each year 2023–2025; this trade is outside those months) |
| 2026-04-15 | Maroney Dawn Christine | President | 30,000 | $626K | 2.8% | Yes | Routine (sold in Mar each year 2023–2025; this trade is outside those months) |
| 2026-04-10…2026-04-13 | Kao John E | Chief Executive Officer | 298,000 | $6.2M | 7.7% | Yes | Routine (traded in Mar each year 2023–2025; this trade is outside those months) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Insider purchases (SEC Form 4, open-market, last ~7 months) (ALHC)
1 purchase, $198K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-06-02 | Kent Mark D. | President - MSO | 14,848 | $198K | 13.31 | Too little history (no open-market trades in 2023–2025) |
Analysts (ALHC)
Consensus Buy (mean 2.07 on a 1–5 scale), 14 analysts; mean target USD 12.31 (low 9, high 26).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | UBS | Target lowered | Neutral | $22 → $9 |
| 2026-10-12 | TD Cowen | Target lowered | Buy | $21 → $12 |
| 2026-10-09 | William Blair | Downgrade | Outperform → Market Perform | |
| 2026-10-09 | JP Morgan | Target lowered | Overweight | $22 → $10 |
| 2026-10-09 | Keybanc | Target lowered | Overweight | $28 → $12 |
| 2026-10-06 | Barclays | Target lowered | Equal-Weight | $16 → $10 |
| 2026-08-04 | JP Morgan | Target lowered | Overweight | $26 → $22 |
| 2026-08-03 | Raymond James | Downgrade | Strong Buy → Outperform | $22 → $19 |
Total return (dividends reinvested) (ALHC)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -51.2% | -57.4% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -51.4% | -15.7% |
| Volatility (annualized) | 71.0% | 65.8% |
| Max drawdown | -69.3% (Jul 2026→Oct 2026) | -78.8% (Nov 2021→Apr 2024) |
ALHC company outlook (results filed Jul 30, 2026)
- “Across All Key Metrics Generates $1.3 billion in total revenue, representing 31.6% growth year-over-year Grows Medicare Advantage membership 31.5% year-over-year to approximately 294,100 members Raises the midpoint of all full-year guidance metrics: membership, revenue, adjusted gross profit and adjusted EBITDA ORANGE, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc.”
Quoted word-for-word from the SEC 8-K results press release.
ALHC analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.04 | $0.14 | -68.5% | $1.31B | 4 |
| Next quarter (ends Dec 2026) | $0.04 | $0.01 | +180.0% | $1.33B | 4 |
| Current fiscal year (ends Dec 2026) | $0.45 | $0.47 | -4.7% | $5.22B | 4 |
| Next fiscal year (ends Dec 2027) | $0.65 | $0.72 | -10.0% | $6.51B | 4 |
ALHC options: expected move
Options price a move of about ±17.7% (±$1.48) by Nov 20, 2026, which includes earnings on Oct 29, 2026. Over the last 8 reports the stock moved ±11% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 71.9% | ±17.7% |
| Dec 18, 2026 | 56 | 66.7% | ±22.6% |
| Jan 15, 2027 | 84 | 61.9% | ±25.3% |
| Feb 19, 2027 | 119 | 66.6% | ±31.9% |
| May 21, 2027 | 210 | 69.0% | ±43.3% |
30-day implied volatility 63.4% vs 102.9% realized over the last 30 trading days. Put/call ratio (volume) 0.07. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 10:07 UTC)
| Price | USD 8.43 |
|---|---|
| Change | ▼ 0.12% (down) |
| Previous Close | USD 8.44 |
| Open | USD 8.44 |
| Day Range | USD 8.35 – 8.55 |
| 52-Week Range | USD 6.01 – 25.12 |
| Volume | 3,037,405 shares |
| Market Cap | $1.75B |
| Exchange | NMS |
Technical Analysis (ALHC)
Nexqual's technical model rates ALHC "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 10:07 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 36.05 (neutral) |
| vs SMA50 | Below (USD 10.52) |
| MACD | -0.57 (negative) |
Analyst Ratings (ALHC)
Wall Street analysts rate ALHC "Buy" based on 14 analysts, with a mean price target of USD 12.31 (range USD 9–26), per Nexqual as of October 23, 2026 at 10:07 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 14 |
| Mean Target | USD 12.31 |
| High Target | USD 26 |
| Low Target | USD 9 |
| Buy / Hold / Sell | 10 / 4 / 0 |
Earnings (ALHC)
| Next Earnings Date | 2026-10-29 |
|---|---|
| EPS Estimate | USD 0.04 |
| Revenue Estimate | $1.31B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.25 vs est 0.2 ▲ beat |
| 2026-03-31 | USD 0.12 vs est 0.09 ▲ beat |
| 2025-12-31 | USD -0 vs est -0.08 ▲ beat |
| 2025-09-30 | USD 0.1 vs est -0.01 ▲ beat |
Source: Nexqual, October 23, 2026 at 10:07 UTC.
Financials & Fundamentals (ALHC)
| Total Revenue | $4.58B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +31.60% |
| Gross Margin | +12.55% |
| Operating Margin | +3.15% |
| Profit Margin | +0.89% |
| ROE | +20.04% |
| Debt / Equity | 1.25 |
| Current Ratio | 1.7 |
| Total Cash | $701.71M |
| Total Debt | $330.50M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $177.51M (3.9% of revenue) |
Source: Nexqual, October 23, 2026 at 10:07 UTC.
Financial Health Score (ALHC)
Nexqual rates Alignment Healthcare, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:07 UTC.
| Growth | Strong — Revenue +46% YoY (annual) |
|---|---|
| Profitability | Weak — Gross margin 13%, operating 3% (last 12 months) |
| Balance Sheet | Mixed — $702M cash and investments vs $324M debt (Jun 2026, SEC), net cash |
| Cash Flow | Mixed — FCF $178M (last 4 quarters to Jun 2026, SEC), slim 3.9% margin |
| Efficiency | Strong — ROE 20%, ROA 3.1% |
Ownership (ALHC)
| Insider Ownership | +2.57% |
|---|---|
| Institutional Ownership | +116.47% |
| Shares Outstanding | 207.44M |
| Float | 188.21M |
| Short % of Float | +11.70% |
Source: Nexqual, October 23, 2026 at 10:07 UTC.
Leadership (ALHC)
Alignment Healthcare, Inc. is led by John E. Kao, Founder, Chairman & CEO, per Nexqual as of October 23, 2026 at 10:07 UTC.
| Founder, Chairman & CEO | John E. Kao |
|---|---|
| Vice Chairman & Executive VP of Corporate Affairs | Joseph Samuel Konowiecki |
| President | Dawn Christine Maroney |
| Chief Financial Officer | James M. Head |
Major Backers & Investors (ALHC)
Notable institutional backers of Alignment Healthcare, Inc. include Wellington Management, FMR, LLC, T. Rowe Price, according to Nexqual as of October 23, 2026 at 10:07 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Wellington Management | 9.05% |
| FMR, LLC | 6.71% |
| T. Rowe Price | 6.32% |
| Invesco | 5% |
| Bank of America Corporation | 4.51% |
| William Blair Investment Management, LLC | 3.74% |
| SmallCap World Fund Inc | 3.56% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 9.56% |
| BlackRock | 9.32% |
| State Street | 3.52% |
Source: Nexqual, October 23, 2026 at 10:07 UTC.
From Alignment Healthcare, Inc.'s Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Our internal care teams and external providers use AVA, our proprietary technology platform, to coordinate high-quality care for members and manage the complexity of the healthcare system.
- The US Department of Health and Human Services, Office for Civil Rights ("OCR") announced on December 27, 2024, and published in the Federal Register on January 6, 2025, a Notice of Proposed Rulemaking proposing extensive modifications to the HIPAA security standards.
- In 2026, penalties for violations of HIPAA and its implementing regulations started at $145 per violation and could not exceed approximately $73,011 per violation, subject to a cap of approximately $2.2 million for violations of the same standard in a single calendar year.] However, a single breach incident can result in violations of multiple standards.
- We applied our clinical and technical expertise to build AVA, a proprietary platform that forms the backbone of our care delivery efforts, whether done through provider partners or directly through our care teams.
Legal & Regulatory Risks (Item 1A, quoted)
- The Health Care Reform Law and Other Current or Future Legislative, Judicial or Regulatory Changes
- Health Insurance Portability and Accountability Act, the Health Information Technology for Economic and Clinical Health Act and Other Laws, Rules and Regulations Related to Data Privacy
- Corporate Practice of Medicine and Other Laws
- Failure to comply with these licensing, certification and accreditation laws, regulations and standards could result in prior payments being subject to recoupment, requirements to make significant changes to our operations and can give rise to civil or, in extreme cases, criminal penalties.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PGNY | Progyny, Inc. | USD 29.12 | ▲ 2.39% |
| CLOV | Clover Health Investments, Corp | USD 4.73 | ▼ 1.05% |
| OSCR | Oscar Health, Inc. | USD 33.32 | ▼ 0.39% |
| MOH | Molina Healthcare Inc | USD 216.64 | ▲ 0.81% |
| CNC | Centene Corporation | USD 71.24 | ▲ 1.42% |
| HUM | Humana Inc. | USD 420.97 | ▼ 1.05% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:07 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt